Incyte | INCY - Należności Handlowe





Należności Handlowe Zmiana Data
Acadia Pharmaceuticals USD 148.38M 153K 2026-03
Agenus USD 22.44M 1.14M 2025-12
Agios Pharmaceuticals USD 16.13M 5.56M 2026-03
Alnylam Pharmaceuticals USD 883.96M 106.39M 2026-03
Amgen USD 9.14B 432M 2026-03
BioCryst Pharmaceuticals USD 106.82M 15.49M 2025-12
Biogen USD 1.79B 76.6M 2026-03
BioMarin Pharmaceutical USD 903.91M 4.3M 2026-03
Bristol-Myers Squibb USD 14.36B 164M 2026-03
Eli Lilly USD 21.18B 1.02B 2026-03
Exelixis USD 328.95M 42.03M 2026-03
Gilead Sciences USD 4.74B 172M 2026-03
Incyte USD 1.05B 27.09M 2026-03
Ionis Pharmaceuticals USD 74M 8M 2026-03
MacroGenics USD 13.37M 55.86M 2025-12
Merck USD 11.78B 345M 2025-12
Moderna USD 71M 113M 2026-03
Nektar Therapeutics USD 1.78M 1.12M 2025-12
Neurocrine Biosciences USD 768.1M 81.3M 2026-03
Novartis USD 9.6B 2.69B 2026-03
Novartis USD 12.29B 3.3B 2025-12
Pfizer USD 16.17B 332M 2026-03
PTC Therapeutics USD 181.62M 21.45M 2025-12
Puma Biotechnology USD 28.1M 3.52M 2024-06
Regeneron Pharmaceuticals USD 5.73B 10.1M 2026-03
Sarepta Therapeutics USD 547.91M 149.68M 2026-03
Ultragenyx Pharmaceutical USD 60M 98M 2026-03
Vertex Pharmaceuticals USD 2B 56.7M 2026-03